Pedersen Gyrithe Lynghøj, Erikson Marie Schmidt, Mogensen Karin, Rosthøj Susanne, Hermann Gregers Gautier
Department of Urology, Herlev-Gentofte Hospital, Capital Region of Denmark, Denmark.
Department of Urology, Herlev-Gentofte Hospital, Capital Region of Denmark, Denmark.
Eur Urol. 2023 Feb;83(2):125-130. doi: 10.1016/j.eururo.2022.08.012. Epub 2022 Sep 2.
Transurethral resection of recurrent low-grade intermediate-risk Ta bladder tumor (BT) in general anesthesia (GA) is burdensome to patients and health care system. Laser technologies enable treatment in office-based settings, reducing morbidity and costs.
To compare 4-mo recurrence-free survival after outpatient department (OPD) diode laser coagulation of BT in local anesthesia and gold standard transurethral resection of BT (TUR-BT) in GA in intermediate-risk Ta low-grade BT, and to evaluate treatment-related morbidity.
DESIGN, SETTING, AND PARTICIPANTS: A prospective randomized noninferiority trial with 4-mo follow-up, in the hospital setting, was conducted in Capital Region of Denmark from 2016 to 2020. Participants were patients with histologically verified Ta low-grade BT recurrence. A total of 206 patients were randomized; 176 finished treatment and follow-up as per protocol.
Laser photocoagulation of bladder tumor (PC-BT) in OPD using a 980 nm diode laser compared with gold standard TUR-BT in GA, both performed with photodynamic diagnosis (PDD) guidance.
Four-month recurrence-free survival was assessed; predefined inferiority criterion was set at 15%. The secondary outcomes were pain during PC-BT, postoperative morbidity, postoperative complications, and patient's preference.
Four-month recurrence-free survival was 8% higher after PC-BT (95% confidence interval [CI]: -8% to 24%). The predefined noninferiority criterion was met. Pain score (1-10) during PC-BT was 2.4 (interquartile range 0.8-3.3). Postoperative lower urinary tract symptom score (0-100) was 13.9 points higher (95% CI: 6.9-21.0, p < 0.001) in the group with transurethral resection of the bladder. The frequency of minor complications was 8.1% higher after TUR-BT (95% CI: 1.0-14.6%, p = 0.026). Of the patients, 98% (95% CI: 92-100%) preferred PC-BT.
PDD-guided PC-BT in OPD is as good as TUR-BT in GA to remove recurrent low-grade Ta BT. Postoperative quality of life is better after PC-BT and the frequency of minor complications was lower.
This study evaluates the efficacy of outpatient laser removal of low-grade noninvasive bladder tumor. Outpatient tumor removal with laser was as good as transurethral resection in general anesthesia and less burdensome to patients.
全身麻醉(GA)下经尿道切除复发性低级别中危Ta期膀胱肿瘤(BT)对患者和医疗保健系统来说负担较重。激光技术能够在门诊环境中进行治疗,从而降低发病率和成本。
比较局部麻醉下门诊用二极管激光凝固治疗中危Ta期低级别BT与全身麻醉下金标准经尿道膀胱肿瘤切除术(TUR-BT)后4个月的无复发生存率,并评估与治疗相关的发病率。
设计、地点和参与者:2016年至2020年在丹麦首都地区的医院环境中进行了一项前瞻性随机非劣效性试验,随访4个月。参与者为经组织学证实的Ta期低级别BT复发患者。共有206例患者被随机分组;176例按方案完成了治疗和随访。
门诊使用980nm二极管激光进行膀胱肿瘤激光光凝术(PC-BT),并与全身麻醉下的金标准TUR-BT进行比较,两者均在光动力诊断(PDD)引导下进行。
评估4个月的无复发生存率;预定义的劣效性标准设定为15%。次要结局为PC-BT期间的疼痛、术后发病率、术后并发症以及患者偏好。
PC-BT后4个月的无复发生存率高8%(95%置信区间[CI]:-8%至24%)。达到了预定义的非劣效性标准。PC-BT期间的疼痛评分(1-10分)为2.4(四分位间距0.8-3.3)。经尿道膀胱切除术组的术后下尿路症状评分(0-100分)高13.9分(95%CI:6.9-21.0,p<0.001)。TUR-BT后轻微并发症的发生率高8.1%(95%CI:1.0-14.6%,p=0.026)。98%(95%CI:92-100%)的患者更喜欢PC-BT。
门诊PDD引导下的PC-BT在切除复发性低级别Ta期BT方面与全身麻醉下的TUR-BT效果相当。PC-BT后的术后生活质量更好,轻微并发症的发生率更低。
本研究评估了门诊激光切除低级别非侵袭性膀胱肿瘤的疗效。门诊激光切除肿瘤与全身麻醉下经尿道切除术效果相当,且对患者的负担更小。